-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on Neurogene, Raises Price Target to $81

Benzinga·08/12/2026 12:31:00
Listen to the news
Guggenheim analyst Debjit Chattopadhyay maintains Neurogene (NASDAQ:NGNE) with a Buy and raises the price target from $69 to $81.